ReviewJournal of diabetes investigation2013
Latest insights into the risk of cancer in diabetes.
Review in Journal of diabetes investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 4 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- The metabolic syndrome-cancer axis: global research trends and clinical landscapes.Frontiers in endocrinology · 2026Pooled it
- A large-scale, observational study to investigate the current status of diabetes complication and their prevention in Japan: incidence/risk factors for malignancies during follow-up-JDCP study 11 (English version).Diabetology international · 2024Guideline
- Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis.Journal of diabetes research · 2019 · on this mapPooled it
- Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.Cancer medicine · 2018Pooled it
- Genetic Evidence Links Gestational Diabetes Mellitus to Increased ER-Negative Breast Cancer Risk Through a Mendelian Randomization Analysis.International journal of endocrinology · 2026Article
- Association of diabetes mellitus and breast cancer in adult men and women: a cross-sectional survey.BMC cancer · 2025Article
- The effects of hsa-mir-26a-5p on cell proliferation, migration, and PI3K inhibitor sensitivity in metformin-resistant triple negative breast cancer cells.Turkish journal of biology = Turk biyoloji dergisi · 2025Article
- Navigating the nexus of type 2 diabetes mellitus and breast cancer: a comprehensive review of co-occurrence.Frontiers in oncology · 2025Review
- Purpurolide C-based microneedle promotes macrophage-mediated diabetic wound healingActa pharmaceutica Sinica. B · 2023Article
- Article
- Causal relationship between obesity and iron deficiency anemia: a two-sample Mendelian randomization study.Frontiers in public health · 2023Article
- Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth.Diabetology international · 2022Article
- Insulin-like Growth Factor 2 mRNA-Binding Protein 2-a Potential Link Between Type 2 Diabetes Mellitus and Cancer.The Journal of clinical endocrinology and metabolism · 2021Review
- Review
- Diabetes and Cancer: Metabolic Association, Therapeutic Challenges, and the Role of Natural Products.Molecules (Basel, Switzerland) · 2021Review
- Multifaceted Mechanisms of Action of Metformin Which Have Been Unraveled One after Another in the Long History.International journal of molecular sciences · 2021Review
- NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells.International journal of molecular sciences · 2020Article
- Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression.Journal of diabetes investigation · 2020Article
- Diabetes and its Potential Impact on Head and Neck Oncogenesis.Journal of Cancer · 2020Review
- Prospective study of cancer in Japanese patients with type 2 diabetes: the Fukuoka Diabetes Registry.Diabetology international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A growing body of evidence from observational studies and meta-analyses of the data suggest that diabetes mellitus is associated with an increased risk of cancer. Meta-analyses have shown that diabetes increases the risks of total cancer, and of site-specific cancers of the breast, endometrium, bladder, liver, colorectum and pancreas, and that it decreases the risk of prostate cancer. Insulin resistance and secondary hyperinsulinemia is the most frequently proposed hypothesis, and hyperglycemia itself might promote carcinogenesis. In addition to several facets of lifestyle including obesity, smoking and lack of exercise, treatment for diabetes might affect the risk of cancer. For instance, metformin, an insulin sensitizer, reportedly has a potential anticancer effect. In light of the exploding global epidemic of diabetes, even a modest increase in the cancer risk will translate into a substantial socioeconomic burden. The current insights underscore the need for clinical attention and better-designed studies of the complex interactions between diabetes and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.